Physician profile
Michael J Severino
NPI 1174591531
$13,941.77
in general payments reported to CMS, 2019-2025
9 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2021: $155 · 2022: $8,647 · 2023: $4,561 · 2024: $190 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $923.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13,132.60 | 2021-2024 | Watchman Access System |
| Kestra Medical Technology Services, INC. | $193.20 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $144.27 | 2023 | Camzyos |
| Abbott Laboratories | $105.58 | 2022-2025 | Cardiomems |
| Abiomed | $94.61 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.43 | 2019 | |
| Novo Nordisk INC | $76.16 | 2019 | |
| Pfizer INC. | $55.59 | 2021-2022 | |
| Akcea Therapeutics, INC. | $52.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Severino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.